SCHEMBL6715391

SCHEMBL6715391

CCOc1ccc(-c2cccc3cc4n(c23)CCNCC4)c(C)c1

nearest known ligand 0.55

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 7/20 0.55
HTR2C P28335 7/20 0.55
PARP1 P09874 2/20 0.36
NMT1 P30419 1/20 0.36
CCNT1 O60563 1/20 0.34
CDK9 P50750 1/20 0.34
RAD52 P43351 1/20 0.33
KMT2A Q03164 1/20 0.33
HTR3E A5X5Y0 1/20 0.32
HTR3B O95264 1/20 0.32
HTR3A P46098 1/20 0.32
HTR3D Q70Z44 1/20 0.32
HTR3C Q8WXA8 1/20 0.32
CACNA2D1 P54289 2/20 0.32
CACNA2D2 Q9NY47 2/20 0.32
MAPT P10636 1/20 0.32
CHRM3 P20309 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6713805 0.89 HTR2A (0.59) HTR2AHTR2CPARP1RAD52KMT2A
SCHEMBL6715823 0.88 HTR2A (0.48) HTR2AHTR2CPARP1HTR3EHTR3B
SCHEMBL6719389 0.84 HTR2A (0.55) HTR2AHTR2CPARP1RAD52KMT2A
SCHEMBL6711057 0.83 HTR2A (0.49) HTR2AHTR2CPARP1HTR3A
SCHEMBL6713804 0.82 HTR2A (0.56) HTR2AHTR2CPARP1KMT2A
SCHEMBL6713197 0.81 HTR2A (0.52) HTR2AHTR2CPARP1HTR3EHTR3B
SCHEMBL6711534 0.81 HTR2A (0.47) HTR2AHTR2CPARP1
SCHEMBL6715371 0.81 HTR2A (0.51) HTR2AHTR2CPARP1
SCHEMBL6714489 0.80 HTR2A (0.45) HTR2AHTR2CPARP1
SCHEMBL6715506 0.79 HTR2A (0.45) HTR2AHTR2CNMT1CCNT1CDK9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US claimed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US claimed
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds PHARMACIA & UPJOHN COMPANY 2002-01-03 US claimed
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds ENNIS MICHAEL DALTON (US) 2004-10-21 US disclosed
US-6734301-B2 5-HT LIGANDS USED TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS PHARMACIA & UPJOHN COMPANY 2004-05-11 US disclosed
EP-1328525-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-A]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2003-07-23 EP disclosed
WO-2001072752-A2 2,3,4,5-TETRAHYDRO-1H-[1,4]DIAZEPINO[1,7-a]INDOLE COMPOUNDS PHARMACIA & UPJOHN COMPANY (US) 2001-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020002161-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HTR1D, HTR1A, HTR1E HTR2A 18/4885HTR2C 7/4885PARP1 1281/4885
US-20040209870-A1 Novel 2,3,4,5-tetrahydro-1H-[1,4]diazepino[1,7-a]indole compounds HCRTR2, NR2C2, RCOR3 HTR2A 1403/4885HTR2C 553/4885PARP1 1140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.